Health Care

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Sees Price Increase - Up by 67.85%

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) Sees Price Increase - Up by 67.85%”

The 50 day moving average was up $4.11 or +65.33% and the 200 day average was up $4.11.

A number of large investors have recently modified their holdings of the company. The value of the investment in (ZYNE) went from $1,516,000 to $1,534,000 a change of $18,000 quarter to quarter.

Zynerba Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. Vanguard Group Inc. now owns 425,811 shares of the company's stock valued at $8,559,000 after purchasing an additional 149,094 shares in the last quarter.

Hain Celestial stock is up 5% at $42.40 thanks to news the company has come to an agreement with activist investor Engaged Capital to overhaul its board, opening the door for a sale of the company down the road. ZYNE shares are up over 70% from yesterday's close of $6.19 and have reached as high as $11.28 in early trading. Zynerba Pharmaceuticals has a one year low of $6.02 and a one year high of $23.75. The company's market cap is $77.42 million. The firm has a 50 day moving average price of $20.69 and a 200 day moving average price of $16.55.

Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) stock has greatly underperformed both the indexes and industry this year. The company reported ($0.71) earnings per share for the quarter, topping analysts' consensus estimates of ($0.75) by $0.04.

As of the latest earnings report the EPS was $-2.60 and is expected to be $-2.42 for the current year with 13,257,000 shares now outstanding.

Several equities research analysts have issued reports on ZYNE shares.

Zynerba Pharmaceuticals, Inc. engages in the research and development of drugs.

On the ratings front, ZYNE stock has been the subject of a number of recent research reports.

August 21 investment analysts at Canaccord Genuity made no change to the stock rating of "Buy" and lowered the price expectation to $9.00 from $35.00. H.C. Wainwright initiated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) on Friday, October 7 with "Buy" rating. Oppenheimer initiated it with "Outperform" rating and $40.0 target in Tuesday, September 8 report. If you are reading this news story on another domain, it was illegally copied and reposted in violation of United States & worldwide trademark and copyright law.

Analysts await Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) to report earnings on November, 13. The reason? The cannabis biotech company announced positive top line results from an open label exploratory Phase 2 FAB-C (Fragile X Syndrome Anxiety and Behavioral Challenges with CBD) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in pediatric and adolescent patients with Fragile X syndrome (FXS).



Like this

Latest


29 September 2017
APOEL ready for Kane test after facing Ronaldo & Messi
Kane wants his trophy room to be similar to the one former England team-mate Rooney has at his mansion. "He is Harry Kane". Tottenham star Harry Kane revealed he used Cristiano Ronaldo and Lionel Messi as motivation to be among the world's best.

29 September 2017
PDC Energy Inc (NASDAQ:PDCE) Q2 2017 Institutional Investor Sentiment Steady
Ten equities research analysts have rated the stock with a hold rating and nineteen have given a buy rating to the stock. Black Creek Investment Management Inc. holds 8.36% of its portfolio in FTI Consulting, Inc. for 4.51 million shares.

29 September 2017
Teen caught having sex with wiener dog, again
The family member who discovered him with the dachshund-mix named Pee Wee at a Warren home reported the incident to authorities. He was charged with four counts of animal cruelty, but now faces two counts of bestiality as well as animal cruelty charges.

29 September 2017
China sets 2019 deadline for automakers to hit green-car sales targets
China is keen to combat air pollution and close a competitive gap between its newer domestic automakers and global rivals. It wants to set goals for electric and plug-in hybrid cars to make up at least a fifth of Chinese auto sales by 2025.

29 September 2017
Aide found half-naked after sexual contact with student, deputies say
Carsey attempted to leave the area when confronted by the deputy, allegedly telling them she was waiting for an adult man. During the investigation, Carsey gave conflicting accounts regarding her involvement with the juvenile victim .

29 September 2017
Chicos Fas Inc (NYSE:CHS) Institutional Investor Positioning Change
For the current quarter Chico's Fas (NYSE:CHS) has high EPS estimates of $0.19 in contradiction of low EPS estimates of $0.12. Also, it has an estimated price-earnings (P/E) multiple of 12 and a trailing 12-month price-earnings (P/E) multiple of 11.73.

29 September 2017
Eaton Vance Ltd Duration Income Fund (EVV) Share Activity Climbing in Session
The RSI, or Relative Strength Index, is a widely used technical momentum indicator that compares price movement over time. Taking a peek at some Moving Averages, the 200-day is at 12.44, the 50-day is 12.58, and the 7-day is sitting at 12.64.

29 September 2017
Bustling Stock in Focus: United States Steel Corporation (NYSE:X)
With 14.10M avg volume, 5 days are for AK Steel Holding Corporation (NYSE:AKS)'s short sellers to cover AKS's short positions. Whereas, in last 21 trading days (one month) was climbed -0.43% and surged in last 63 trading days (quarter) of 11.61%.

29 September 2017
Lam Research Corporation (NASDAQ:LRCX) Under Analyst Spotlight
Reinhart Partners Inc increased Bok Finl Corp Com New (NASDAQ:BOKF) stake by 39,345 shares to 274,135 valued at $23.06M in 2017Q2. The semiconductor company reported $3.11 EPS for the quarter, topping the Zacks' consensus estimate of $3.02 by $0.09.

29 September 2017
Louisiana Principal: Stand for Anthem or Lose Roster Spot
Indeed, schools should respect students who embrace their constitutional rights and stand up to injustice - not punish them. Schools have no valid interest in turning their students into mouthpieces of government speech, full stop.



Recommended